Trial Outcomes & Findings for A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliability of an Autoinjector (NCT NCT02124798)

NCT ID: NCT02124798

Last Updated: 2018-04-11

Results Overview

The primary objective was to assess the suitability of the auto injector for self-administration of belimumab. An overall assessment of usability and reliability for the device was determined by assessing the rate of successfully complete self-administered injections relative to attempted ones. The assessment for the parameter, drug successfully injected was elicited by a Yes/No response. The participants who were able to administer injections inside and outside of the clinic without assistance were included.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

95 participants

Primary outcome timeframe

Weeks 1 and 2 (Inside clinic)

Results posted on

2018-04-11

Participant Flow

This was a study in participants with Systemic Lupus Erythematosus (SLE). The study was conducted at 27 centers in the United States from 20 May 2014 to 13 April 2015.

A total of 119 participants were screened out of which only 95 were enrolled to the study treatment. 25 were screen failures the reasons for which were did not meet inclusion/exclusion criteria (23), lost to follow up (1), withdrew consent (1).

Participant milestones

Participant milestones
Measure
Total
Eligible participants self administered once weekly dose of 200 milligram per milliliter (mg/mL), of belimumab subcutaneously (SC) into thigh or abdomen with an auto-injector device for 8 weeks. Of which 4 of the doses were administered under observation in the clinic (week 1, 2, 4 and week 8) under the supervision of investigator and 4 of the doses were administered outside the clinic and without observation (week 3, 5,6 and week 7).
Overall Study
STARTED
95
Overall Study
COMPLETED
91
Overall Study
NOT COMPLETED
4

Reasons for withdrawal

Reasons for withdrawal
Measure
Total
Eligible participants self administered once weekly dose of 200 milligram per milliliter (mg/mL), of belimumab subcutaneously (SC) into thigh or abdomen with an auto-injector device for 8 weeks. Of which 4 of the doses were administered under observation in the clinic (week 1, 2, 4 and week 8) under the supervision of investigator and 4 of the doses were administered outside the clinic and without observation (week 3, 5,6 and week 7).
Overall Study
Adverse Event
3
Overall Study
Lost to Follow-up
1

Baseline Characteristics

A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliability of an Autoinjector

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Belimumab 200mg Auto Injector
n=95 Participants
Eligible participants self administered once weekly dose of 200 mg/mL, of belimumab SC into thigh or abdomen with an auto-injector device for 8 weeks. Of which 4 of the doses were administered under observation in the clinic (week 1, 2, 4 and week 8) under the supervision of investigator and 4 of the doses were administered outside the clinic and without observation (week 3, 5,6 and week 7).
Age, Continuous
44.8 Years
STANDARD_DEVIATION 12.50 • n=93 Participants
Sex: Female, Male
Female
88 Participants
n=93 Participants
Sex: Female, Male
Male
7 Participants
n=93 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=93 Participants
Race (NIH/OMB)
Asian
3 Participants
n=93 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=93 Participants
Race (NIH/OMB)
Black or African American
23 Participants
n=93 Participants
Race (NIH/OMB)
White
69 Participants
n=93 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=93 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=93 Participants

PRIMARY outcome

Timeframe: Weeks 1 and 2 (Inside clinic)

Population: The intention-to-treat (ITT) population was defined as all participants who were enrolled and treated with at least 1 dose of belimumab. Only those participants with data available at the indicated time points were analyzed.

The primary objective was to assess the suitability of the auto injector for self-administration of belimumab. An overall assessment of usability and reliability for the device was determined by assessing the rate of successfully complete self-administered injections relative to attempted ones. The assessment for the parameter, drug successfully injected was elicited by a Yes/No response. The participants who were able to administer injections inside and outside of the clinic without assistance were included.

Outcome measures

Outcome measures
Measure
Belimumab 200mg Auto Injector
n=90 Participants
Eligible participants self administered once weekly dose of 200 mg/mL, of belimumab SC into thigh or abdomen with an auto-injector device for 8 weeks. Of which 4 of the doses were administered under observation in the clinic (week 1, 2, 4 and week 8) under the supervision of investigator and 4 of the doses were administered outside the clinic and without observation (week 3, 5,6 and week 7).
Number of Participants Successfully Able to Self-administer Their Observed First and Second Doses in Weeks 1 and 2 (Inside Clinic)
Week 1 and 2, YES
89 Participants
Number of Participants Successfully Able to Self-administer Their Observed First and Second Doses in Weeks 1 and 2 (Inside Clinic)
Week 1 and 2, NO
1 Participants

SECONDARY outcome

Timeframe: Weeks 4 and 8 (Inside clinic)

Population: ITT population. Only those participants with data available at the indicated time points were analyzed.

The main objective was to assess the suitability of the auto injector for self-administration of belimumab by participants with SLE. An overall assessment of usability and reliability for the device was determined by assessing the rate of successfully complete self-administered injections relative to attempted ones. The assessment for the parameter, drug successfully injected was elicited by a Yes/No response. The participants who were able to administer injections inside and outside of the clinic without assistance were included.

Outcome measures

Outcome measures
Measure
Belimumab 200mg Auto Injector
n=87 Participants
Eligible participants self administered once weekly dose of 200 mg/mL, of belimumab SC into thigh or abdomen with an auto-injector device for 8 weeks. Of which 4 of the doses were administered under observation in the clinic (week 1, 2, 4 and week 8) under the supervision of investigator and 4 of the doses were administered outside the clinic and without observation (week 3, 5,6 and week 7).
Number of Participants Successfully Able to Self-administer Their Observed Doses in Weeks 4 and 8 (Inside Clinic)
Week 4 and 8, YES
85 Participants
Number of Participants Successfully Able to Self-administer Their Observed Doses in Weeks 4 and 8 (Inside Clinic)
Week 4 and 8, NO
2 Participants

SECONDARY outcome

Timeframe: Weeks 3, 5, 6, and 7 (Outside clinic)

Population: ITT population. Only those participants with data available at the indicated time points were analyzed.

Assessment was performed for suitability of the auto injector for self-administration of belimumab by participant with SLE outside the clinic setting. An overall assessment of usability and reliability for the device was determined by assessing the rate of successfully complete self-administered injections relative to attempted ones. The assessment for the parameter, drug successfully injected was elicited by a Yes/No response. The participants who were able to administer injections outside of the clinic without assistance were included.

Outcome measures

Outcome measures
Measure
Belimumab 200mg Auto Injector
n=87 Participants
Eligible participants self administered once weekly dose of 200 mg/mL, of belimumab SC into thigh or abdomen with an auto-injector device for 8 weeks. Of which 4 of the doses were administered under observation in the clinic (week 1, 2, 4 and week 8) under the supervision of investigator and 4 of the doses were administered outside the clinic and without observation (week 3, 5,6 and week 7).
Number of Participants Who Reported They Were Successfully Able to Self-administer Their Doses Outside the Clinic Setting in Weeks 3, 5, 6, and 7 (Outside Clinic)
Weeks 3, 5, 6 and 7, YES
81 Participants
Number of Participants Who Reported They Were Successfully Able to Self-administer Their Doses Outside the Clinic Setting in Weeks 3, 5, 6, and 7 (Outside Clinic)
Weeks 3, 5, 6 and 7, NO
6 Participants

Adverse Events

Belimumab 200mg Auto Injector

Serious events: 4 serious events
Other events: 28 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Belimumab 200mg Auto Injector
n=95 participants at risk
Eligible participants self administered once weekly dose of 200 mg/mL, of belimumab SC into thigh or abdomen with an auto-injector device for 8 weeks. Of which 4 of the doses were administered under observation in the clinic (week 1, 2, 4 and week 8) under the supervision of investigator and 4 of the doses were administered outside the clinic and without observation (week 3, 5,6 and week 7).
Blood and lymphatic system disorders
Anaemia
1.1%
1/95 • From start of treatment (Day 0, week 1) up to week 12
All adverse events (AEs) and serious AEs (SAEs) were collected from the first dosing day (Day 0) to Week 12. The ITT population was used for analysis.
Blood and lymphatic system disorders
Neutropenia
1.1%
1/95 • From start of treatment (Day 0, week 1) up to week 12
All adverse events (AEs) and serious AEs (SAEs) were collected from the first dosing day (Day 0) to Week 12. The ITT population was used for analysis.
Infections and infestations
Pneumonia
1.1%
1/95 • From start of treatment (Day 0, week 1) up to week 12
All adverse events (AEs) and serious AEs (SAEs) were collected from the first dosing day (Day 0) to Week 12. The ITT population was used for analysis.
Infections and infestations
Postoperative abscess
1.1%
1/95 • From start of treatment (Day 0, week 1) up to week 12
All adverse events (AEs) and serious AEs (SAEs) were collected from the first dosing day (Day 0) to Week 12. The ITT population was used for analysis.
General disorders
Pyrexia
1.1%
1/95 • From start of treatment (Day 0, week 1) up to week 12
All adverse events (AEs) and serious AEs (SAEs) were collected from the first dosing day (Day 0) to Week 12. The ITT population was used for analysis.
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
1.1%
1/95 • From start of treatment (Day 0, week 1) up to week 12
All adverse events (AEs) and serious AEs (SAEs) were collected from the first dosing day (Day 0) to Week 12. The ITT population was used for analysis.
Vascular disorders
Deep vein thrombosis
1.1%
1/95 • From start of treatment (Day 0, week 1) up to week 12
All adverse events (AEs) and serious AEs (SAEs) were collected from the first dosing day (Day 0) to Week 12. The ITT population was used for analysis.

Other adverse events

Other adverse events
Measure
Belimumab 200mg Auto Injector
n=95 participants at risk
Eligible participants self administered once weekly dose of 200 mg/mL, of belimumab SC into thigh or abdomen with an auto-injector device for 8 weeks. Of which 4 of the doses were administered under observation in the clinic (week 1, 2, 4 and week 8) under the supervision of investigator and 4 of the doses were administered outside the clinic and without observation (week 3, 5,6 and week 7).
Infections and infestations
Bronchitis
3.2%
3/95 • From start of treatment (Day 0, week 1) up to week 12
All adverse events (AEs) and serious AEs (SAEs) were collected from the first dosing day (Day 0) to Week 12. The ITT population was used for analysis.
Infections and infestations
Sinusitis
3.2%
3/95 • From start of treatment (Day 0, week 1) up to week 12
All adverse events (AEs) and serious AEs (SAEs) were collected from the first dosing day (Day 0) to Week 12. The ITT population was used for analysis.
Infections and infestations
Gastroenteritis viral
2.1%
2/95 • From start of treatment (Day 0, week 1) up to week 12
All adverse events (AEs) and serious AEs (SAEs) were collected from the first dosing day (Day 0) to Week 12. The ITT population was used for analysis.
Infections and infestations
Herpes zoster
2.1%
2/95 • From start of treatment (Day 0, week 1) up to week 12
All adverse events (AEs) and serious AEs (SAEs) were collected from the first dosing day (Day 0) to Week 12. The ITT population was used for analysis.
Infections and infestations
Nasopharyngitis
2.1%
2/95 • From start of treatment (Day 0, week 1) up to week 12
All adverse events (AEs) and serious AEs (SAEs) were collected from the first dosing day (Day 0) to Week 12. The ITT population was used for analysis.
Infections and infestations
Urinary tract infection
2.1%
2/95 • From start of treatment (Day 0, week 1) up to week 12
All adverse events (AEs) and serious AEs (SAEs) were collected from the first dosing day (Day 0) to Week 12. The ITT population was used for analysis.
Gastrointestinal disorders
Nausea
6.3%
6/95 • From start of treatment (Day 0, week 1) up to week 12
All adverse events (AEs) and serious AEs (SAEs) were collected from the first dosing day (Day 0) to Week 12. The ITT population was used for analysis.
Gastrointestinal disorders
Diarrhoea
3.2%
3/95 • From start of treatment (Day 0, week 1) up to week 12
All adverse events (AEs) and serious AEs (SAEs) were collected from the first dosing day (Day 0) to Week 12. The ITT population was used for analysis.
Gastrointestinal disorders
Vomiting
2.1%
2/95 • From start of treatment (Day 0, week 1) up to week 12
All adverse events (AEs) and serious AEs (SAEs) were collected from the first dosing day (Day 0) to Week 12. The ITT population was used for analysis.
Musculoskeletal and connective tissue disorders
Arthralgia
4.2%
4/95 • From start of treatment (Day 0, week 1) up to week 12
All adverse events (AEs) and serious AEs (SAEs) were collected from the first dosing day (Day 0) to Week 12. The ITT population was used for analysis.
Musculoskeletal and connective tissue disorders
Systemic lupus erythematosus
3.2%
3/95 • From start of treatment (Day 0, week 1) up to week 12
All adverse events (AEs) and serious AEs (SAEs) were collected from the first dosing day (Day 0) to Week 12. The ITT population was used for analysis.
Musculoskeletal and connective tissue disorders
Bursitis
2.1%
2/95 • From start of treatment (Day 0, week 1) up to week 12
All adverse events (AEs) and serious AEs (SAEs) were collected from the first dosing day (Day 0) to Week 12. The ITT population was used for analysis.
General disorders
Fatigue
2.1%
2/95 • From start of treatment (Day 0, week 1) up to week 12
All adverse events (AEs) and serious AEs (SAEs) were collected from the first dosing day (Day 0) to Week 12. The ITT population was used for analysis.
General disorders
Injection site erythema
2.1%
2/95 • From start of treatment (Day 0, week 1) up to week 12
All adverse events (AEs) and serious AEs (SAEs) were collected from the first dosing day (Day 0) to Week 12. The ITT population was used for analysis.
General disorders
Malaise
2.1%
2/95 • From start of treatment (Day 0, week 1) up to week 12
All adverse events (AEs) and serious AEs (SAEs) were collected from the first dosing day (Day 0) to Week 12. The ITT population was used for analysis.
Nervous system disorders
Headache
2.1%
2/95 • From start of treatment (Day 0, week 1) up to week 12
All adverse events (AEs) and serious AEs (SAEs) were collected from the first dosing day (Day 0) to Week 12. The ITT population was used for analysis.

Additional Information

GSK Response Center

GlaxoSmithKline

Phone: 866-435-7343

Results disclosure agreements

  • Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
  • Publication restrictions are in place

Restriction type: OTHER